ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pitolisant

Also written as “Pitolisant”, “Open-label Pitolisant” and “Pitolisant Oral Tablet”.

Its studies are mostly in Prader-Willi Syndrome · Idiopathic Hypersomnia · Myotonic Dystrophy · Disorders of Excessive Somnolence · Diabetes Mellitus, Type 1, led by 3 companies.

Drug pagePitolisant: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 1, 20218 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Harmony Biosciencesits history only62 open or runningphase 3since Dec 1, 2021Jan 29, 2020Apr 2027phase 3 · NCT06366464
Citrine Medicine10 open or runningphase 3since Jan 24, 2022Jan 24, 2022none ahead
High Point Clinical Trials Centerits history only10 open or runningphase 1since Jul 17, 2019Jul 17, 2019none ahead

Also a collaborator on its studies: Ferox Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Citrine Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2022First study: phase 3 study in Disorders of Excessive SomnolenceFirst studyNCT05223166 · 240 enrolled · China

TargetBeta

HRH3 →read by rule
“Histamine H3 receptor inverse agonist; Histamine H3 receptor inverse agonist”ChEMBL 37, by rule

Other programs on HRH3

ProgramCompanyFurthest phaseStudies
samelisantrulesuven-life-sciences-limitedphase 33

Studies

The one study Citrine Medicine leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05223166Disorders of Excessive Somnolence · China3CompletedJul 18, 2023240

How it is read

Names in the registry

  • “Pitolisant”, 4 entries
  • “Open-label Pitolisant”, 1 entry
  • “Pitolisant Oral Tablet”, 1 entry
  • “Pitolisant tablet”, 1 entry
  • “Pitolisant oral tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.